Access cutting-edge graft-versus-host disease treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.
Access graft-versus-host disease specialists in Chicago at no cost
This study follows strict safety protocols and ethical guidelines
All study-related graft-versus-host disease treatment provided free
The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years.
Sponsor: Deciphera Pharmaceuticals, LLC
Check if you qualify for this graft-versus-host disease clinical trial in Chicago, IL
If you're searching for graft-versus-host disease treatment options in Chicago, IL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced graft-versus-host disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.